Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer

Abstract excerpt

Immunotherapy has transformed advanced non-small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long-lasting responses in some patients. However, the molecular determinants driving these long-term responses remain elusive. To address this issue, we performed an integrative analysis of genomic and transcriptomic features of long-term immune checkpoint inhibitors (ICIs)-associated...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Cancer Immunotherapy and Biomarkers
• Share to Lung Cancer Treatments and Mutations